Starling Oncology (STLN)
Community cancer-care platform combining clinics, specialty pharmacy, and value-based payer contracts.
Something off on this page? Send us feedback.
Delivers community-based cancer care, specialty pharmacy, and clinical research through affiliated clinics and a contracted network. Revenue combines treatment and pharmacy services with value-based contracts that place it at risk for oncology costs.
Combines community oncology practices and independent-provider networks with value-based payer contracts, fee-for-service treatment, specialty pharmacy, and clinical research. Care teams provide medical oncology, hematology, infusions, radiation oncology, transfusions, and around-the-clock support, while pharmacy fills medications tied to oncology care.
Operates directly affiliated clinics across California, Florida, Arizona, Oregon, and Nevada, alongside a wider contracted network concentrated in part in Florida. Its hybrid model pairs provider reach with clinical pathways, payer contracting, and administrative services.
Earns most revenue from specialty pharmacy and patient services. Professional corporations retain clinical decision-making, while long-term management-services agreements supply billing, collections, finance, records, and staffing infrastructure.
Assumes medical-cost risk under capitated contracts and depends on payer reimbursement, pharmacy-benefit-manager access, drug procurement, clinician capacity, and government-program rules.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $41.1M · Total debt $104.5M · Total assets $178.2M · Shareholders' equity −$24.9M
- Revenue
- $161.3M
- Operating income
- −$4.6M
- Net income
- −$9.8M
No dividends on record.
| Insiders2 holders · as of Aug 24, 2026 | 11.07% | 11.07M shares | |
| Otherremainder | 88.93% | 88.91M shares |
99.98M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Jorey ChernettInsider10 percent owner | 10.66% | 10.66M | Form 4filed Aug 17, 2026 ↗ |
Brad HivelyInsiderdirector | 0.41% | 411,976 | Form 4filed Aug 24, 2026 ↗ |
Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Brad Hively | director | −298,853 | $6.51 |
| Aug 13, 2026 | Jorey Chernett | 10 percent owner | −100 | $9.00 |
| Aug 14, 2026 | Jorey Chernett | 10 percent owner | +12,000 | $6.54 |
- McKesson
Community oncology network rival with deep practice-support scale.
- Cencora
Community oncology MSO and specialty-distribution rival.
- Evolent
Oncology benefit-management rival for health-plan contracts.
- CVS Health
Oncology specialty-pharmacy and benefit-management rival.
- Cigna
Specialty-pharmacy rival for oncology prescriptions and benefits.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Starling Oncology | $5.95 | −2.30% | $608.9M | — | — | 1.0 | +34.6% |
| McKesson | $926.66 | +0.16% | $108.27B | 24.7 | 20.0 | 0.3 | +7.7% |
| Cencora | $336.40 | +0.02% | $65.44B | 25.0 | 17.3 | 0.2 | +5.1% |
| Evolent | $4.23 | +0.12% | $475.8M | — | 12.6 | 0.2 | +46.9% |
| CVS Health | $97.23 | −0.01% | $124.06B | 25.7 | 12.0 | 0.3 | +7.3% |
| Cigna | $284.76 | +0.68% | $74.74B | 11.7 | 8.9 | 0.3 | +6.6% |
| Median | 24.9 | 12.6 | 0.3 | +7.3% |